Trump's Global Drug Price Model: Challenges Ahead
Published on: June 30, 2026, 3:32 p.m. | Source: Devdiscourse
President Donald Trump's initiative to replicate global drug pricing in the U.S. is facing hurdles, particularly with mid-sized pharmaceutical companies. While 17 major drugmakers have signed on to the most-favored-nation pricing model, smaller companies remain reluctant due to potential impacts on their business models and profit margins.
